SCHEMBL2148984

SCHEMBL2148984

CCCCC1CCCCN1CCCn1c(=O)oc2c(Cl)cc(Cl)c(Cl)c21

nearest known ligand 0.40

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 3/20 0.40
S1PR3 Q99500 3/20 0.40
S1PR5 Q9H228 3/20 0.40
DRD2 P14416 4/20 0.38
DRD1 P21728 2/20 0.38
DRD4 P21917 2/20 0.38
DRD5 P21918 2/20 0.38
DRD3 P35462 2/20 0.38
S1PR4 O95977 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
HSD17B10 Q99714 2/20 0.34
TSHR P16473 1/20 0.34
RECQL P46063 1/20 0.34
ALOX15 P16050 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13742015 0.81 CHRM1 (0.43) DRD2DRD4DRD3TSHRNPSR1
SCHEMBL2150189 0.75 S1PR1 (0.40) S1PR1S1PR3S1PR5S1PR4RECQL
SCHEMBL7029673 0.69 S1PR1 (0.61) S1PR1S1PR3S1PR5S1PR4SMN1; SMN2
Fluoride SCHEMBL29251951 0.68 S1PR1 (0.60) S1PR1S1PR3S1PR5S1PR4SMN1; SMN2
Fluoride SCHEMBL30330461 0.67 S1PR1 (0.62) S1PR1S1PR3S1PR5S1PR4SMN1; SMN2
SCHEMBL30550081 0.67 S1PR1 (0.57) S1PR1S1PR3S1PR5S1PR4
Fluoride SCHEMBL30330997 0.66 S1PR1 (0.65) S1PR1S1PR3S1PR5S1PR4SMN1; SMN2
Fluoride SCHEMBL30330439 0.66 S1PR1 (0.65) S1PR1S1PR3S1PR5S1PR4SMN1; SMN2
Hydrochloric Acid SCHEMBL30331012 0.66 S1PR1 (0.65) S1PR1S1PR3S1PR5S1PR4
Fluoride SCHEMBL30330748 0.66 S1PR1 (0.65) S1PR1S1PR3S1PR5S1PR4SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1432420-B1 BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS ACADIA PHARM INC (US) 2011-07-13 EP disclosed
US-20100216840-A1 BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS ACADIA PHARMACEUTICALS INC. (US) 2010-08-26 US disclosed
US-7300928-B2 Benzimidazolidinone derivatives as muscarinic agents ACADIA PHARMACEUTICALS, INC. (US) 2007-11-27 US disclosed
US-7291611-B2 Benzimidazolidinone derivatives as muscarinic agents ACADIA PHARMACEUTICALS INC. (US) 2007-11-06 US disclosed
US-7273857-B2 Benzimidazolidinone derivatives as muscarinic agents ACADIA PHARMACEUTICALS INC. (US) 2007-09-25 US disclosed
US-20060258707-A1 Benzimidazolidinone derivatives as muscarinic agents KELLY NICHOLAS M 2006-11-16 US disclosed
US-20060205785-A1 Benzimidazolidinone derivatives as muscarinic agents KELLY NICHOLAS M 2006-09-14 US disclosed
US-20060199799-A1 Benzimidazolidinone derivatives as muscarinic agents KELLY NICHOLAS M 2006-09-07 US disclosed
US-7087593-B2 Benzimidazolidinone derivatives as muscarinic agents ACADIA PHARMACEUTICALS INC. (US) 2006-08-08 US disclosed
US-20060025402-A1 Benzimidazolidinone derivatives as muscarinic agents KELLY NICHOLAS M 2006-02-02 US disclosed
US-6951849-B2 Benzimidazolidinone derivatives as muscarinic agents ACADIA PHARMACEUTICALS INC. (US) 2005-10-04 US disclosed
US-20040067931-A1 Benzimidazolidinone derivatives as muscarinic agents ACADIA PHARMACEUTICALS INC. 2004-04-08 US disclosed
US-20030100545-A1 Benzimidazolidinone derivatives as muscarinic agents ACADIA PHARMACEUTICALS, INC. 2003-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030100545-A1 Benzimidazolidinone derivatives as muscarinic agents CHRM4, CHRM5, CHRM1 S1PR1 639/4885S1PR3 735/4885S1PR5 719/4885
US-20060258707-A1 Benzimidazolidinone derivatives as muscarinic agents CHRM4, CHRM1, CHRM2 S1PR1 650/4885S1PR3 710/4885S1PR5 763/4885
US-20100216840-A1 BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS CHRM4, CHRM1, CHRM2 S1PR1 650/4885S1PR3 710/4885S1PR5 763/4885
US-20060025402-A1 Benzimidazolidinone derivatives as muscarinic agents CHRM4, CHRM1, CHRM2 S1PR1 650/4885S1PR3 710/4885S1PR5 763/4885
US-20040067931-A1 Benzimidazolidinone derivatives as muscarinic agents CHRM4, CHRM5, CHRM1 S1PR1 639/4885S1PR3 735/4885S1PR5 719/4885
US-20060199799-A1 Benzimidazolidinone derivatives as muscarinic agents CHRM4, CHRM1, CHRM2 S1PR1 650/4885S1PR3 710/4885S1PR5 763/4885
US-20060205785-A1 Benzimidazolidinone derivatives as muscarinic agents CHRM4, CHRM1, CHRM2 S1PR1 650/4885S1PR3 710/4885S1PR5 763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.